Epidermal growth factor receptor-dependent cytotoxic effect of anti-EGFR antibody-ribonuclease conjugate on human cancer cells

Tatsushi Suwa, Masakazu Ueda, Hiromitsu Jinno, Soji Ozawa, Yuko Kitagawa, Nobutoshi Ando, Masaki Kitajima

Research output: Contribution to journalArticle

16 Citations (Scopus)


We have conjugated the murine monoclonal antibody (528) against the human epidermal growth factor receptor (EGFR) to mammalian pancreatic ribonuclease (RNase) via N-succinimidyl-3-(2-pyridyldithio) propionate (SPDP) and 2-iminothiolene (2-IT). The conjugate showed dose-dependent cytotoxicity against EGFR-producing squamous cancer cells (A431, TE8, TE5, Ca9-22) and no detectable cytotoxicity against EGFR-deficient small-cell lung cancer cells (H69). The cytotoxicity of the conjugate was positively correlated with the EGFR numbers of each cell line. The addition of excess 528 antibody to the medium protected A431 cells from the conjugate cytotoxicity. This immuno-conjugate might be useful for targeted treatment of squamous cell carcinomas hyperexpressing EGFR.

Original languageEnglish
Pages (from-to)4161-4165
Number of pages5
JournalAnticancer research
Issue number5 B
Publication statusPublished - 1999 Dec 25



  • Conjugate
  • Epidermal growth factor receptor
  • Ribonuclease

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this